Akroswiss

Akroswiss is a Swiss biopharmaceutical company dedicated to developing nasal spray treatments for claustrophobia and seizure medications. Akroswiss has successfully developed and tested a unique dual-dose nasal drug delivery device with first-class 360° functionality to address two unmet clinical needs: effective treatment of seizures (rescue medication use) and conscious sedation prior to diagnostic intervention for claustrophobia and agitation (anxiolytic medication use). Akroswiss is seeking European market authorization for its midazolam product portfolio and is currently compiling all the necessary documents for submission to the EMA.